FDA approves new type of antipsychotic drug, a potential ‘game changer’
Washington Post
The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna Therapeutics.
https://www.washingtonpost.com/business/2024/09/26/fda-antipsychotic-mental-illness-alzheimers/